Yttrium-90 radioembolotherapy for hepatocellular cancer

Ravi Murthy; Pritesh Mutha; Sanjay Gupta

doi:10.1007/978-1-60327-522-4_20

Yttrium-90 radioembolotherapy for hepatocellular cancer

Ravi Murthy, Pritesh Mutha, Sanjay Gupta

Interventional Radiology

Research output: Chapter in Book/Report/Conference proceeding › Chapter

3 Scopus citations

Abstract

Hepatocellular carcinoma (HCC) accounts for between 85 and 90% of primary liver cancers. Over a million cases of hepatocellular cancer occur annually making it the fifth most common cancer worldwide and the third most common cause of cancer mortality. In the United States, the incidence of HCC has steadily increased over the past two decades, with an estimated 21,370 new cases having occurred in 2008 [1]. HCC-related mortality has increased in parallel with 18,410 estimated deaths during the same time period [1]. In addition, the incidence of HCC in patients with both known risks such as hepatitis C and unknown risk factors is increasing [2].

Original language	English (US)
Title of host publication	Hepatocellular Carcinoma
Subtitle of host publication	Targeted Therapy and Multidisciplinary Care
Publisher	Springer New York
Pages	319-335
Number of pages	17
ISBN (Print)	9781603275217
DOIs	https://doi.org/10.1007/978-1-60327-522-4_20
State	Published - 2011

Keywords

Hepatocellular cancer
Yttrium-90

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-1-60327-522-4_20

Cite this

@inbook{f0f10a2eb8094cb28c2df96736944054,

title = "Yttrium-90 radioembolotherapy for hepatocellular cancer",

abstract = "Hepatocellular carcinoma (HCC) accounts for between 85 and 90% of primary liver cancers. Over a million cases of hepatocellular cancer occur annually making it the fifth most common cancer worldwide and the third most common cause of cancer mortality. In the United States, the incidence of HCC has steadily increased over the past two decades, with an estimated 21,370 new cases having occurred in 2008 [1]. HCC-related mortality has increased in parallel with 18,410 estimated deaths during the same time period [1]. In addition, the incidence of HCC in patients with both known risks such as hepatitis C and unknown risk factors is increasing [2].",

keywords = "Hepatocellular cancer, Yttrium-90",

author = "Ravi Murthy and Pritesh Mutha and Sanjay Gupta",

year = "2011",

doi = "10.1007/978-1-60327-522-4_20",

language = "English (US)",

isbn = "9781603275217",

pages = "319--335",

booktitle = "Hepatocellular Carcinoma",

publisher = "Springer New York",

}

TY - CHAP

T1 - Yttrium-90 radioembolotherapy for hepatocellular cancer

AU - Murthy, Ravi

AU - Mutha, Pritesh

AU - Gupta, Sanjay

PY - 2011

Y1 - 2011

N2 - Hepatocellular carcinoma (HCC) accounts for between 85 and 90% of primary liver cancers. Over a million cases of hepatocellular cancer occur annually making it the fifth most common cancer worldwide and the third most common cause of cancer mortality. In the United States, the incidence of HCC has steadily increased over the past two decades, with an estimated 21,370 new cases having occurred in 2008 [1]. HCC-related mortality has increased in parallel with 18,410 estimated deaths during the same time period [1]. In addition, the incidence of HCC in patients with both known risks such as hepatitis C and unknown risk factors is increasing [2].

AB - Hepatocellular carcinoma (HCC) accounts for between 85 and 90% of primary liver cancers. Over a million cases of hepatocellular cancer occur annually making it the fifth most common cancer worldwide and the third most common cause of cancer mortality. In the United States, the incidence of HCC has steadily increased over the past two decades, with an estimated 21,370 new cases having occurred in 2008 [1]. HCC-related mortality has increased in parallel with 18,410 estimated deaths during the same time period [1]. In addition, the incidence of HCC in patients with both known risks such as hepatitis C and unknown risk factors is increasing [2].

KW - Hepatocellular cancer

KW - Yttrium-90

UR - http://www.scopus.com/inward/record.url?scp=84889981146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889981146&partnerID=8YFLogxK

U2 - 10.1007/978-1-60327-522-4_20

DO - 10.1007/978-1-60327-522-4_20

M3 - Chapter

AN - SCOPUS:84889981146

SN - 9781603275217

SP - 319

EP - 335

BT - Hepatocellular Carcinoma

PB - Springer New York

ER -

Yttrium-90 radioembolotherapy for hepatocellular cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this